Scarica l'app Stockscreener
1.31
4.76%
0.05
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché PHIO Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.26
Aprire:
$1.27
Volume 24 ore:
72,799
Relative Volume:
0.02
Capitalizzazione di mercato:
$15.28M
Reddito:
-
Utile/perdita netta:
$-8.70M
Rapporto P/E:
-0.8711
EPS:
-1.5039
Flusso di cassa netto:
$-7.99M
1 W Prestazione:
+11.86%
1M Prestazione:
+23.36%
6M Prestazione:
-40.81%
1 anno Prestazione:
+1.50%
Intervallo 1D:
$1.27
$1.3375
Intervallo di 1 settimana:
$1.18
$1.3375
Portata 52W:
$0.8127
$4.1899
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Nome
Phio Pharmaceuticals Corp
Settore
Industria
Telefono
(508) 767-3861
Indirizzo
411 SWEDELAND ROAD, KING OF PRUSSIA, MA
Compare PHIO vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
1.315 | 14.64M | 0 | -8.70M | -7.99M | -1.5039 |
VRTX
Vertex Pharmaceuticals Inc
|
451.39 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
754.55 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
329.82 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
687.64 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.26 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-05 | Ripresa | H.C. Wainwright | Buy |
| 2020-08-05 | Iniziato | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Borsa (PHIO) Ultime notizie
Phio Pharmaceuticals to present PH-762 cancer trial data Friday By Investing.com - Investing.com South Africa
Phio Pharmaceuticals to present PH-762 cancer trial data Friday - Investing.com
Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement - marketscreener.com
A skin cancer study with 65% response sends Phio to a late-breaker stage - Stock Titan
Cancer biotech Phio Pharmaceuticals stock surges as trial shows tumor clearance at highest dose in skin cancer patients - MSN
PHIO Stock Price, Quote & Chart | PHIO PHARMACEUTICALS CORP (NASDAQ:PHIO) - ChartMill
Aug Macro: Is Phio Pharmaceuticals Corp a stock for growth or value investors2026 Historical Comparison & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Retail Trends: Is Phio Pharmaceuticals Corp being accumulated by smart money2026 Performance Recap & Daily Entry Point Trade Alerts - baoquankhu1.vn
Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family Office - Bitget
Phio cancer study sees ~65% response; CEO in March 18 virtual chat - Stock Titan
Sidoti Boosts Earnings Estimates for Phio Pharmaceuticals - Defense World
PHIO: RNA therapy for skin cancer shows 85% response and no toxicities, advancing to pivotal trials - TradingView
Phio Pharmaceuticals Corp. Financial Disclosures & SEC Filings - TradingView
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDT - GlobeNewswire
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT - TMX Newsfile
Cancer gene-silencing trial shows 65% response in Phio study - Stock Titan
How Phio Pharmaceuticals Corp. stock compares to industry benchmarksBuy Signal & High Accuracy Trade Signal Alerts - Naître et grandir
EV Market: Is Phio Pharmaceuticals Corp being accumulated by smart moneyJuly 2025 Sector Moves & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update - marketscreener.com
Cancer drug PH-762 completes safety phase as Phio raises $23.7M - Stock Titan
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series - marketscreener.com
Phio cancer drug PH-762 posts 65% response; CEO hosts live Q&A - Stock Titan
Phio Pharmaceuticals Reports 2025 Financial Results, Extends Cash Runway into 2027 - National Today
PHIO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin Cancer Patients - Sahm
PHIO Should I Buy - Intellectia AI
PHIO Technical Analysis & Stock Price Forecast - Intellectia AI
Phio Pharmaceuticals Corp. Selected as B2i Digital Featured Company - Weekly Voice
Phio Pharmaceuticals Reports Promising Phase 1b Results for Skin Cancer Therapy, Plans FDA Submission for 2026 - citybuzz -
Phio Pharmaceuticals Aligns Leadership Team to Support Next Stage Development of PH-762 and Advancement of PH-894 - The Courier-Journal
Is Phio Pharmaceuticals Corp. stock trending bullish2025 Major Catalysts & Advanced Technical Analysis Signals - mfd.ru
Phio Pharmaceuticals Boosts CEO Severance and Incentive Compensation - TipRanks
Phio reshapes leadership as PH-762 cancer drug nears key tests - Stock Titan
CEO contract changes at Phio (NASDAQ: PHIO) lift bonus target - Stock Titan
CVI and Heights disclose 9.9% Phio (PHIO) stake based on warrant holdings - Stock Titan
Will Phio Pharmaceuticals Corp. benefit from rising consumer demandWeekly Investment Report & Advanced Swing Trade Entry Alerts - mfd.ru
What are Phio Pharmaceuticals Corp.’s growth leversInsider Buying & AI Forecast for Swing Trade Picks - mfd.ru
DealFlow Discovery Conference: Opportunities Unveiled - timothysykes.com
Can Phio Pharmaceuticals Corp. lead its sector in growthEarnings Growth Summary & Growth Focused Stock Reports - mfd.ru
Phio Pharmaceuticals Corp. (PHIO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
PHIO Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Aug Closing: Is Phio Pharmaceuticals Corp. being accumulated by smart moneyJuly 2025 Reactions & Real-Time Chart Breakout Alerts - mfd.ru
What's Going On With Tiny Cancer Biotech Phio Pharmaceuticals On Thursday? - Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Best Penny Stocks To Watch Now – February 10th - Defense World
DealFlow Events Sets Stage for PEIO Stock Momentum - StocksToTrade
Phio reports positive results from PH-762 skin cancer trial By Investing.com - Investing.com Australia
Phio Pharmaceuticals (PHIO) stock rises premarket as new PH-762 skin cancer data keeps traders circling - TechStock²
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Phio reports positive results from PH-762 skin cancer trial - Investing.com South Africa
Phio Pharmaceuticals Corp Azioni (PHIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Phio Pharmaceuticals Corp Azioni (PHIO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Bitterman Robert J | Chairman, Pres. & CEO |
Dec 23 '25 |
Buy |
1.02 |
5,000 |
5,100 |
286,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Nov 21 '25 |
Buy |
1.14 |
5,000 |
5,700 |
281,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Nov 18 '25 |
Buy |
1.27 |
5,000 |
6,350 |
276,421 |
| Bitterman Robert J | Chairman, Pres & CEO |
Jun 10 '25 |
Buy |
2.42 |
2,000 |
4,840 |
27,149 |
| Ferrara Robert L | Director |
Jun 10 '25 |
Buy |
2.42 |
2,500 |
6,050 |
15,666 |
| Bitterman Robert J | Chairman, Pres & CEO |
Jun 09 '25 |
Buy |
2.75 |
1,500 |
4,125 |
25,149 |
| Bitterman Robert J | Chairman, Pres & CEO |
May 21 '25 |
Buy |
1.77 |
3,000 |
5,310 |
22,449 |
| Bitterman Robert J | Chairman, Pres & CEO |
May 22 '25 |
Buy |
1.78 |
1,200 |
2,136 |
23,649 |
| Ferrara Robert L | Director |
May 20 '25 |
Buy |
1.82 |
2,500 |
4,550 |
13,166 |
0.99%
3.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):